United Therapeutics (UTHR)
(Real Time Quote from BATS)
$330.08 USD
+7.85 (2.44%)
Updated Aug 8, 2024 01:46 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 501 - 520 ( 601 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
June And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials Beat on Top Line And Double-Digit Growth Intact; 2013 Focus Remains On New Products And Growth; Reiterate OUTPERFORM & $91 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Believe Consensus Is Achievable; In 2013, We See New Product Progress And Continued Sales Growth; Reiterate OUTPERFORM And $91 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2012 Financials Beat And Double Digit Growth Intact. Near- Term Focus Remains On March 31st PDUFA For Oral Treprostinil. Reiterate OUTPERFORM & $91 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Consensus Is Achievable, But Focus Is On March 31st PDUFA For Oral Treprostinil
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Pulling A Rabbit Out Of Its Hat: FDA Accepts Rapid Resubmission Of Oral Treprostinil NDA With Class 1 Review And March 31 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Revenues And Earnings Beat (Again) And We Project Consistent Double Digit Growth Through 2016. Reiterate OUTPERFORM and $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L